The primary vision of the UCD Academic Centre in Translational Oncology (ACTO) is to (a) acknowledge and foster the exceptional cancer initiatives already in place, with a particular focus on gaining international recognition within academic and industrial sectors, and (b) to unify the basic, translational and clinical cancer research communities across all UCD affiliated hospitals. Dublin East Hospitals, Institutes and Schools. The ACTO translational research agenda envisages collaboration with other centres of cancer research activity (physical and virtual) to improve patient outcomes.

Translational Oncology is the crucial bridge that enables application of scientific discoveries into clinical practice with the intention of improving clinical outcomes of cancer treatment. This can only be achieved by establishing a critical mass of clinicians and researchers, driven by a similar agenda. The recent creation of the Dublin East network of hospitals provides a catchment population in excess of one million and includes two of the eight designated cancer centres in Ireland (Mater Misericordiae University Hospital and St Vincent’s University Hospital) that together currently treat the largest numbers of patients affected by all the major cancers (Breast, Prostate, Colorectal, Lung, Pancreas) within the country. This critical mass provides opportunities for enhanced basic research collaboration but also crucially will greatly enhance interactions with the pharmaceutical and medical device industries.

ACTO has obtained commitments from over 50 colleagues in UCD to move this collaborative research agenda forward. The group represents a cross-section of UCD cancer research interests. Formal recognition as an Academic Centre in Translational Oncology will greatly enhance applications for significant national and international funding including the Irish Cancer Society Collaborative Cancer Research Centres programme, the SFI Centres call and the Horizon 2020 Funding Programme.

The ACTO group includes active PIs in computational biology, innovative model systems including canine, rodent, zebra fish and xenopus model systems, high-throughput proteomic and biomarker discovery platforms, substantial cancer tissue cohorts (through the Prostate Cancer Research Consortium, Molecular Therapeutics for Cancer Ireland, the TNBC Mater/SVUH alliance, CRC), synthetic chemistry, chemical biology and imaging. Moreover, Systems Biology Ireland (SBI) led by Professor Walter Kolch (Director, UCD Conway Institute) gives an exceptional pathway analysis approach integral to deciphering the complexity that cancer displays. As the ACTO develops, it will be in a very strong position to strategically recruit expertise as required.

The ACTO group published over 90 peer reviewed publications, while securing Euro 7 million in funding. Recognition of the proposed Academic Centre will consolidate efforts in continuing to secure additional significant funding to support the unified agenda of translational oncology research.

Translational Oncology
Dr Amanda McCann
Senior Lecturer
Location: UCD Conway Institute
Contact: 01 716 6757
Email: amanda.mccann@ucd.ie

My research focuses on the mechanisms underlying Paclitaxel (Taxol®) chemoresistance for women presenting with epithelial ovarian cancer (EOC) and Triple Negative Breast Cancer (TNBC) specifically the spindle assembly checkpoint (SAC) and autophagy in the face of chemotherapeutic agents. I am also interested in profiling DNA methylation and histone modification signatures in hypoxia and how this relates to ultimate chemoresistance and the retention of cellular viability (senescence/autopaging) in the face of chemotherapeutic engagement.

I am also Group coordinator of the UCD/Mater Misericordiae University Hospital Triple Negative Breast Cancer (TNBC) Group. In addition, I am leading the submission of a proposal to the UCD authority for an Academic Centre in Translational Oncology.

Researchers Supported:
Mr Alejandro Merino, PhD - Post-doctoral Researcher
Dr Amin Laskami, PhD - SMMS student
Dr Georgi Valchev, PhD - Research Assistant
Dr Micheal Looney, PhD - Tutor/Research Fellow
Dr Georgina Flood, PhD - SMMS student
Ms Sara O’Kane, Research Assistant

Prof Dolores Cahill
Professor of Translational Science
Location: UCD Conway Institute
Contact: 01 716 6677 / 086 172 5572
Email: dolorescahill@ucd.ie

My group is involved in translating biomarkers to benefit patients, from their use in improved diagnosis, including in applications in Ovarian Cancer (Murphy et al 2011a; Murphy et al 2012b) and in understanding the underlying lethal cancer causation and progression with our collaborators in Ireland, MD Anderson Cancer Centre, Texas, USA (Staquicini, et al, 2012) and Lund Cancer Centre, Lund (Olsen et al, 2013).

Researchers Supported:
Dr Menaul Murphy, PhD - Post-Doctoral Researcher
Prof John Cowan, St Vincent’s University Hospital
MSc O’Kane - Research Assistant (co-supervised with Prof Cowan, Mater Hospital)
Dr Ann Laskam, PhD - post-doctoral researcher
Dr Fidelma Flanagan, SMMS student
Ms Joana Cornwall, PhD - Researcher
Mr Aodhain Beazee, PhD - Researcher
Ms Maese Daly, SMMS student

Dr Maria Bengoechea Alonso
Research Fellow
Location: UCD Conway Institute
Contact: 01 716 7663
Email: maria.bengoechea-alonso@ucd.ie

We work on the SRBEP family of transcription factors. These proteins control cholesterol and lipid metabolism and play critical roles during adipocyte differentiation and insulin-dependent gene expression. Disturbances in lipid metabolism are at the very core of several major health issues facing modern society, including cardiovascular disease, obesity and diabetes. Thus, the factors and signals that regulate the function of the SRBEP family of proteins are very relevant to metabolic disease.

Prof Michael J. Duffy
Professor (Adjunct)
Location: Clinical Research Centre, St Vincent’s University Hospital
Contact: 01 716 5814
Email: michaelj.duffy@ucd.ie

Our research focuses on the identification and validation of new biomarkers and therapeutic targets for breast cancer. This work is being carried out in collaboration with other Molecular Therapeutics.
My research is focused on the molecular pathology of colorectal cancer. Much of this research is carried out in collaboration with the Centre for Colorectal Disease at St. Vincent’s University Hospital. Using array technology we are assessing methylation levels at multiple sites across the genome to determine how patterns of methylation relate to the traditional classifications of colorectal cancer. Results are validated using pyrosequencing and immunohistochemistry to facilitate integration of our findings into patient care.

Researchers Supported:
Dr Maciej Milewski, PhD

External Collaborators:
Centres for Colorectal Diseases, St. Vincent’s University Hospital, Dublin

Prof Patricia MacMathuna
Associate Clinical Professor

Location: Mater Misericordiae University Hospital
Contact: 01 830 4226 / 087 262 2742
Email: p.macmathuna@materrae


Established working research collaboration with Prof John Reynolds and Prof Jacinta O’Sullivan, TCD on Barrett’s Registry and Biomolecular investigation (multi centre study). Dr David Gallagher, Mater on HNPCC Malignancy profile in Irish Pedigree.

Prof Peter O’Gorman
Director of Pathology and Consultant Haematologist, Mater Misericordiae University Hospital

Location: Mater Misericordiae University Hospital
Contact: Email: pogramm@materrae

I am Director of Pathology and consultant haematologist at the Mater University Hospital, an academic teaching hospital allied to University College Dublin, Dublin, Ireland. As Director of Pathology he leads and manages a staff of 130. The haematology department has four specialist colleagues who treat a range of hematologic malignancies. In 2008 he established the MIRT-Ireland translational research group with Prof Ken Anderson from the Dana Farber Cancer Institute in Boston and Prof Martin O’Reilly, National Institute for Cellular Biotechnology, Dublin City University. Dr O’Gorman’s primary role is director of the clinical program, management of biospecimen samples, and clinical trials. He is also a professor of medical doctors who undertake a PhD as part of the MIRT-Ireland Dana Farber Cancer Institute MD-PhD Myeloma Academy. MIRT-Ireland is taking a lead in Ireland in the development of a companion diagnostic program for Multiple Myeloma. This recently resulted in the first patented predictive therano-sis test (reference 4). Dr O’Gorman is the current chair of the national clinical trials program with the Irish Clinical Oncology Research Group (www.icorg.ie). He is a founder member of and clinical trials lead for the Myeloma Ireland Consortium.

Researchers Supported:
Ms Catriona Hayes, PhD
Dr Abdul Hameed, PhD
Mr Nicholas Hegarty, MD

Dr Peter O’Gorman
Professor of Proteomics

Location: UCD Conway Institute
Contact: 01 716 6783
Email: stephen.pennington@ucd.ie

Current research interests and well-funded projects (Health Research Board, Movember, Enterprise Ireland, Irish Cancer Society) are focussed on the mass spectrometry based discovery, measurement and validation of protein biomarkers – predominantly in oncology and inflammatory disease. Projects are undertaken in collaboration with scientific and clinical colleagues – within UCD and between institutions in Dublin/Inland and internationally as a part of significant consortia. 2012 saw the development of a new biomarker validation lab in partnership with Agilent Technologies.

Collaborators:
Prof Stephen Pennington, UCD Conway Institute of Biomolecular & Biomedical Research
Prof William Watson, UCD Conway Institute of Biomolecular & Biomedical Research
Prof Pauline Fudd, UCD Conway Institute of Biomolecular & Biomedical Research
Prof Brendan Murphy, UCD School of Mathematics and Physical Science
Prof Patrick Cunningham, UCD School of Computer Science & Data Engineering
Prof Elaine Kay, Department of Pathology, Royal College of Surgeons in Ireland
Prof Richard O’Keeffe, Biomedical Diagnostic Institute, Dublin City University
Prof John O’Leary, Department of Pathology, Trinity College Dublin
Dr Antoinette Perry, Department of Urology, Trinity College Dublin
Dr Aoife MacNamara, UCD Conway Institute of Biomedical & Biomedical Research

As a translational biologist based at the Conway Institute I utilise latest technologies to study the cellular and molecular pathways of prostate cancer. I use this knowledge to address clinically relevant questions via my clinical collaborators as part of the Prostate Cancer Research Consortium and Molecular Therapeutics for Cancer in Ireland. These studies have identified novel biomarkers for patient stratification into appropriate treatment groups and targets for therapeutic manipulation which we are validating with our national collaborators as part of the Movember Global Action Plan and ToPCaP.

Collaborators:
Prof Stephen Pennington, UCD Conway Institute of Biomolecular & Biomedical Research
Prof William Watson, UCD Conway Institute of Biomolecular & Biomedical Research
Prof Pauline Fudd, UCD Conway Institute of Biomolecular & Biomedical Research
Prof Brendan Murphy, UCD School of Mathematics and Physical Science
Prof Patrick Cunningham, UCD School of Computer Science & Data Engineering
Prof Elaine Kay, Department of Pathology, Royal College of Surgeons in Ireland
Prof Richard O’Keeffe, Biomedical Diagnostic Institute, Dublin City University
Prof John O’Leary, Department of Pathology, Trinity College Dublin
Dr Antoinette Perry, Clinical Medicine, Trinity College Dublin, St James Hospital

Dr Antonio Fedele, Department of Pathology, Trinity College Dublin, St James Hospital

Dr Richard Power, Division of Urology, Beaumont Hospital

Prof Tom Lynch, Department of Urology, Trinity College Dublin, St James Hospital

Dr Cecily Quin
Senior Clinical Lecturer

Location: St. Vincent’s University Hospital
Contact: Email: cqquin@st-vincents.ie

Triple negative breast carcinoma (TNBC) is an aggressive form of invasive breast carcinoma with an adverse prognosis for many patients. The ongoing challenge is to identify targets that may lead to the development of specific treatment regimes for this type of breast carcinoma that is currently poorly responsive to chemotherapy. I am an active member of the collaborative TNBC research group, between St. Vincent’s University Hospital and Dublin City University, established in 2009 by Prof John Crown. Our group has recently published on the expression of two proteins, mTOR and Src, in TNBC.

I am also working collaboratively with Dr Amanda McCann and her research team at UCD, investigating the expression and significance of Mad2 in TNBC.

Dr Dermot Leahy
Senior Biochemist

Location: UCD Conway Institute
Contact: 01 716 6551
Email: dermot.leahy@ucd.ie

My research is focused on the molecular pathology of colorectal cancer. Much of this research is carried out in collaboration with the Centre for Colorectal Disease at St. Vincent’s University Hospital. Using array technology we are assessing methylation levels at multiple sites across the genome to determine how patterns of methylation relate to the traditional classifications of colorectal cancer. Results are validated using pyrosequencing and immunohistochemistry to facilitate integration of our findings into patient care.

Researchers Supported:
Dr Maciej Milewski, PhD

External Collaborators:
Centres for Colorectal Diseases, St. Vincent’s University Hospital, Dublin

Prof Patricia MacMathuna
Associate Clinical Professor

Location: Mater Misericordiae University Hospital
Contact: 01 830 4226 / 087 262 2742
Email: p.macmathuna@materrae


Established working research collaboration with Prof John Reynolds and Prof Jacinta O’Sullivan, TCD on Barrett’s Registry and Biomolecular investigation (multi centre study). Dr David Gallagher, Mater on HNPCC Malignancy profile in Irish Pedigree.

Prof Peter O’Gorman
Professor of Proteomics

Location: UCD Conway Institute
Contact: 01 716 6783
Email: stephen.pennington@ucd.ie

Current research interests and well-funded projects (Health Research Board, Movember, Enterprise Ireland, Irish Cancer Society) are focussed on the mass spectrometry based discovery, measurement and validation of protein biomarkers – predominantly in oncology and inflammatory disease. Projects are undertaken in collaboration with scientific and clinical colleagues – within UCD and between institutions in Dublin/Inland and internationally as a part of significant consortia. 2012 saw the development of a new biomarker validation lab in partnership with Agilent Technologies.

Collaborators:
Prof Stephen Pennington, UCD Conway Institute of Biomolecular & Biomedical Research
Prof William Watson, UCD Conway Institute of Biomolecular & Biomedical Research
Prof Pauline Fudd, UCD Conway Institute of Biomolecular & Biomedical Research
Prof Brendan Murphy, UCD School of Mathematics and Physical Science
Prof Patrick Cunningham, UCD School of Computer Science & Data Engineering
Prof Elaine Kay, Department of Pathology, Royal College of Surgeons in Ireland
Prof Richard O’Keeffe, Biomedical Diagnostic Institute, Dublin City University
Prof John O’Leary, Department of Pathology, Trinity College Dublin
Dr Antoinette Perry, Clinical Medicine, Trinity College Dublin, St James Hospital

Dr Antonio Fedele, Department of Pathology, Trinity College Dublin, St James Hospital

Dr Richard Power, Division of Urology, Beaumont Hospital

Prof Tom Lynch, Department of Urology, Trinity College Dublin, St James Hospital

Dr Cecily Quin
Senior Clinical Lecturer

Location: St. Vincent’s University Hospital
Contact: Email: cqquin@st-vincents.ie

Triple negative breast carcinoma (TNBC) is an aggressive form of invasive breast carcinoma with an adverse prognosis for many patients. The ongoing challenge is to identify targets that may lead to the development of specific treatment regimes for this type of breast carcinoma that is currently poorly responsive to chemotherapy. I am an active member of the collaborative TNBC research group, between St. Vincent’s University Hospital and Dublin City University, established in 2009 by Prof John Crown. Our group has recently published on the expression of two proteins, mTOR and Src, in TNBC.

I am also working collaboratively with Dr Amanda McCann and her research team at UCD, investigating the expression and significance of Mad2 in TNBC.
Grants:

Title: The Fate of Chemoresistance in Triple Negative Breast Cancer (TNBC)
Funder: The Mater Surgical Oncology Research Appeal/ University College Dublin Foundation Ltd.
Start/End Dates: 11-JUL-11 / 11-JUL-13
Amount: €50,000

Title: A therapeutic roadmap for ovarian cancer using MvD88-MAD2 as prognostic indicators
Funder: Royal City of Dublin Hospital Trust
Start/End Dates: 01-SEP-12 / 01-SEP-15
Amount: €67,101

Title: The anti-IL6 antibody siltuximab enhances the efficacy of Paclitaxel (Taxol) in triple negative breast cancer cells (TNBCs) by inhibiting the induction of viable chemoresistant senescent cells.
Funder: Eccles Breast Health Research Fund (EBHR)
Start/End Dates: 01-SEP-12 / 01-SEP-13
Amount: €10,000

Title: Tumour Derived Exosomes (TEXs) from Paclitaxel Cultured Triple Negative Breast Cancer (TNBC) Cells Affects Resultant Chemoresistance in Naïve Parent Cell Lines
Funder: The Mater Surgical Oncology Research Appeal/ University College Dublin Foundation Ltd.
Start/End Dates: 11-JUL-12 / 11-JUL-14
Amount: €160,000

Title: Translational studies on anaesthesia and cancer progression
Funder: Sisk Foundation
Start/End Dates: 2010-2012
Amount: €240,000

Title: Pharmaceuticals policies: Policies that determine which drugs are reimbursed
Funder: Health Research Board (HRB)
Start/End Dates: 01-DEC-10 / 31-DEC-13 (extended)
Amount: €97,978

Title: Colonisation by sulphate reducing bacteria (SRB) subspecies in normal and inflamed colon and colonocyte responses to the SRB metabolite hydrogen sulphide
Funder: Science Foundation Ireland (SFI)
Start/End Dates: 10-JUL-10 / 10-JUL-15
Amount: €647,750

Title: The effect of CTGF polymorphisms on surgical recurrence following terminal ileal resection for Crohn’s disease.
Funder: Health Research Board (HRB)
Start/End Dates: 10-JUL-10 / 10-JUL-15
Amount: €647,750

Title: Translational Oncology

Funder: University College Dublin (UCD)
Start/End Dates: 01-MAR-12 / 31-OCT-13
Amount: €96,449

Funder: International Fund (IF)
Start/End Dates: 01-SEP-12 / 01-SEP-15
Amount: €40,000

Funder: Boston Scientific
Start/End Dates: 01-SEP-12 / 01-SEP-15
Amount: €40,000

Funder: Health Research Board (HRB)
Start/End Dates: 01-OCT-09 / 31-OCT-14
Amount: €9,999

Funder: Science Foundation Ireland (SFI)
Start/End Dates: 01-OCT-09 / 31-OCT-14
Amount: €109,978

Funder: Science Foundation Ireland (SFI)
Start/End Dates: 01-OCT-09 / 31-OCT-14
Amount: €109,978

Funder: IIBD Fellowship
Start/End Dates: 2011-12 and 2012-3
Amount: €40,000 x 2 (€80,000)

Funder: Enterprise Ireland CFI Grant
Start/End Dates: 2012-3
Amount: €100,000

Funder: Enterprise Ireland
Start/End Dates: 2012-3
Amount: €100,000

Funder: Science Foundation Ireland (SFI)
Start/End Dates: 01-JUL-11 / 30-JUN-15
Amount: €156,000

Title: ADAM10: A NEW PLAYER IN BREAST CANCER PROGRESSION?
Funder: University College Dublin (UCD)
Start/End Dates: 01-MAR-12 / 31-OCT-13
Amount: €96,449

Title: Molecular therapeutics for cancer: translational research to individualise therapy with targeted agents
Funder: Science Foundation Ireland (SFI)
Start/End Dates: 01-SEP-12 / 01-SEP-15
Amount: €40,000

Title: Molecular therapeutics for cancer: translational research to individualise therapy with targeted agents
Funder: Science Foundation Ireland (SFI)
Start/End Dates: 01-SEP-12 / 01-SEP-15
Amount: €40,000
<table>
<thead>
<tr>
<th>Reference</th>
<th>Title and Authors</th>
<th>Journal</th>
<th>Year</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>32.</td>
<td>Bone Marrow Res 2011, 64</td>
<td>2011</td>
<td>98</td>
<td>2011</td>
</tr>
<tr>
<td>40.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>62.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>63.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>64.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>65.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>66.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>67.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>68.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>69.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>70.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>71.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>72.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>73.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>74.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>75.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>76.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>77.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>78.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>79.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>80.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>81.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>82.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>83.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>84.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>85.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>86.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>87.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>88.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>89.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>90.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>91.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>92.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>93.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>94.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>95.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>96.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>97.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>98.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>100.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>101.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>102.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>103.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>104.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>105.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>106.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>107.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>108.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
<tr>
<td>110.</td>
<td>Mol Cancer 2011, 10</td>
<td>2011</td>
<td>10</td>
<td>2011</td>
</tr>
</tbody>
</table>

Note: The references are presented in a table format for clarity and easy reference.


